Evogene Ltd.

EVGN Nasdaq SEC CIK 1574565
Follow Evogene Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10M$20MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$3.9M-
FY24$5.6M−$16.5M
FY23$3M−$23.9M
FY22$1.7M−$26.6M
FY21$930K−$27.8M
FY20$1M−$23.4M
FY19$753K−$18.1M
FY18$1.7M−$20.8M
FY17$3.4M−$20.8M
FY16$6.5M−$19.6M
FY15$11.1M−$17.2M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25−6.3%−364.2%-
FY2457.3%−337.2%−295.6%
FY2350%−745.5%−800.8%
FY2245.7%−1608.4%−1590.3%
FY2117.5%−3328.3%−2988.5%
FY2044.8%−2386%−2247.5%
FY1955.6%−2810.9%−2405.3%
FY1816.9%−1144.2%−1188.2%
FY1715.9%−649.1%−616.3%
FY1613.8%−322.5%−299.6%
FY1525.8%−161%−154.7%
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$13.6M
FY24−$20.3M
FY23−$22.2M
FY22−$24.8M
FY21−$25.6M
FY20−$20.2M
FY19−$18.6M
FY18−$15.5M
FY17−$16.5M
FY16−$12.5M
FY15−$14.4M
FY14-
Net margin vs the sectorMedian of Materials companies filing with the SEC
  • Evogene Ltd.
  • Materials median
−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearEvogene Ltd.Materials median
FY25-2.3%
FY24−295.6%3.4%
FY23−800.8%4.4%
FY22−1590.3%5.6%
FY21−2988.5%6.4%
FY20−2247.5%4.1%
FY19−2405.3%4.1%
FY18−1188.2%5%
FY17−616.3%4.9%
FY16−299.6%4.8%
FY15−154.7%3.3%
FY14-4.5%